Studying adults with essential thrombocythemia who later develop polycythemia vera
Looks back at adults with essential thrombocythemia who later develop polycythemia vera.
Key facts
- Who runs it
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Where
- London, United KingdomSee the siteAlso in 4 other countries, 23 sites
- Trial code
- Registry title
- A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
- Status
- Recruiting
- People taking part
- 678 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 3 groups
- Record updated
- 9 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with essential thrombocythemia (ET) who carry the JAK2V617F change and later developed polycythemia vera (PV). It also uses ET and PV control groups.
- Age
- 18 to 100 years
- Sex
- All sexes can join.
- Disease stage
- Essential thrombocythemia that progressed to polycythemia vera by 31/12/2020. Both diagnoses follow the 2022 international consensus classification.
- Biomarker or test result
- JAK2V617F positive.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- ET patients (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) who are JAK2V617F positive and have progressed to PV (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) by 31/12/2020. The date of PV diagnosis will be defined as the index date and this group of patients will be defined as ET-to-PV cases
Who cannot take part
- None
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in United Kingdom
Also in 4 other countries, 23 sites
- Guy's and St Thomas' NHS Foundation TrustLondon, United KingdomContact: Claire Harrison, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
International multicenter retrospective observational study consisting of two parts: a nested case-control study (part A) and a comparative retrospective cohort study (part B).
The 3 groups in the trial
- ET to PV patients
Patients JAK2V617F positive and who have progressed to PV by 31/12/2020.
- ET patients
Patients JAK2V617F positive who did not progress to PV after a comparable period of time. This control group will be selected using a 1:1 matched case-control design.
- PV de novo patients
Patients diagnosed with de novo PV (no progression from previous ET). This control group will be recruited using a 1:1 matching procedure.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Unmasking Polycythemia Vera in Long-Standing Essential Thrombocythemia: A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
- Plain-language title
- Studying adults with essential thrombocythemia who later develop polycythemia veraGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07203768, who can take part
- Publications
- Record updated
- 9 July 2026